# RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

> **NCT01188889** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** RAD001
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT01188889
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-09
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to obtain sufficient funding.
- **Last updated:** 2015-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188889, "RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01188889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*